Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Q2 2022 vs. Q1 2022
How the institutions holding Alvotech changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 0 | 17 | +17 |
| Shares | 0 | 19.4M | +19.4M |
| Value | $0 | $157.8M | +$157.8M |
New holders (17)
Institutions that held Alvotech at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bracebridge Capital, LLC | 6,981,387 | $57.3M | 18.72% |
| Oaktree Capital Management LPSuperinvestorOaktree Capital | 6,338,660 | $52.0M | 0.62% |
| Lodbrok Capital LLP | 2,074,345 | $14.5M | 0.81% |
| Temasek Holdings (Private) Ltd | 1,000,000 | $8.21M | 0.04% |
| Suvretta Capital Management, LLC | 1,000,000 | $8.21M | 0.31% |
| Sculptor Capital LP | 700,000 | $6.61M | 0.07% |
| Oaktree Fund Advisors, LLC | 667,367 | $5.48M | 9.61% |
| Farallon Capital Management, L.L.C. | 500,000 | $4.11M | 0.02% |
| Millennium Management LLC | 52,442 | $431.0K | 0.00% |
| Jane Street Group, LLC | 41,060 | $337.0K | 0.00% |
| Narwhal Capital Management | 24,000 | $197.0K | 0.03% |
| UBS Group AG | 13,646 | $112.0K | 0.00% |
| Gamco Investors, Inc. Et Al | 13,447 | $110.0K | 0.00% |
| Penserra Capital Management LLC | 2,639 | $21.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,487 | $20.0K | 0.00% |
| Morgan Stanley | 1,792 | $15.0K | 0.00% |
| Barclays PLC | 1,256 | $10.0K | 0.00% |
Sold out (0)
Institutions that held Alvotech at the end of Q1 2022 and filed for Q2 2022 without it.
None.